drugset / Trial / NCT02768649

Single Ascending Dose Study of RBP-7000

NCT02768649

Phase 1 Completed 45 enrolled Indivior Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia

Timeline

Start
2011-04
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Background Risperidone Other / unclassified Subcutaneous
Background Risperidone Other / unclassified 0.25 mg Oral

Indications